Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with acute and chronic pain. Founded in 2006, Heron has made significant strides in the industry, particularly with its proprietary formulations that enhance patient outcomes while minimising opioid use. The company’s flagship products, including the non-opioid analgesic Zynrelef and the anti-emetic agent Cinvanti, stand out for their unique delivery mechanisms and efficacy. Heron Therapeutics has established a strong market position, recognised for its commitment to improving patient care through science-driven solutions. With a robust pipeline and a dedication to addressing unmet medical needs, Heron continues to shape the future of pain management and supportive care in the healthcare landscape.
DitchCarbon Score
How does Heron Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Heron Therapeutics, Inc.'s score of 20 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Heron Therapeutics, Inc.'s reported carbon emissions
Heron Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives related to climate commitments. Without specific emissions figures or defined goals, it is challenging to assess their environmental impact or progress in reducing carbon emissions. The absence of data may indicate a need for further transparency in their sustainability efforts. As the industry increasingly prioritises climate action, Heron Therapeutics may benefit from establishing clear emissions reduction strategies and commitments to align with best practices in environmental stewardship.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Heron Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
